Cost and effectiveness analyses of the anti-osteoporosis medication in patients with hip fracture in Taiwan: A population-based national claims database analysis.
Chen-Yu Wang, Chih-Hsing Wu, Ho-Min Chen...
https://pubmed.ncbi.nlm.nih.gov/37574339/Actively Recruiting
Led by National Taiwan University Hospital · Updated on 2026-06-23
70
Participants Needed
1
Research Sites
35 weeks
Total Duration
The trial investigates treatment approaches for osteoporosis in postmenopausal women aged 50 to 90 years. It compares a 24-month cyclic therapy regimen of Romosozumab followed by Denosumab repeated twice versus a traditional sequential therapy of 12 months Romosozumab followed by 12 months Denosumab. Osteoporosis is common in this population and can lead to fractures that reduce quality of life and increase mortality. The study aims to optimize drug strategies to improve patient outcomes. Participants will receive either Romosozumab monthly for 12 months followed by Denosumab every six months for 12 months, or a cycle therapy where Romosozumab is given monthly for 6 months, followed by one dose of Denosumab, then repeated once more after 6 months. This randomized controlled trial evaluates which regimen better affects bone health over two years. Throughout the study, participants will undergo bone mineral density BMD assessments at baseline and every 6 months up to 24 months. Bone turnover markers, pain levels via visual analogue scale, disability index scores, fracture occurrence, and adverse events will also be monitored at various intervals. This detailed monitoring supports evaluation of treatment efficacy and safety during the 24-month intervention period.
CONDITIONS
Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients
F
Fon-Yih Tsuang
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Taiwan University Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 24 months
Participants receive either the cyclic therapy with Romosozumab and Denosumab repeated twice over 24 months or the sequential therapy with 12 months Romosozumab followed by 12 months Denosumab. The goal is to compare the effects of these regimens on bone health.
Regular visits for assessments at baseline, 3, 6, 9, 12, 13, 15, 18, 21, and 24 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Chen-Yu Wang, Chih-Hsing Wu, Ho-Min Chen...
https://pubmed.ncbi.nlm.nih.gov/37574339/Bárbara Gehrke, Maria Caroline Alves Coelho, Catarina Brasil d'Alva...
https://pubmed.ncbi.nlm.nih.gov/37948565/Ian R Reid, Emma O Billington
https://pubmed.ncbi.nlm.nih.gov/35279261/Felicia Cosman, Daria B Crittenden, Jonathan D Adachi...
https://pubmed.ncbi.nlm.nih.gov/27641143/Chen-Yu Wang, Shau-Huai Fu, Rong-Sen Yang...
https://pubmed.ncbi.nlm.nih.gov/29067572/M S LeBoff, S L Greenspan, K L Insogna...
https://pubmed.ncbi.nlm.nih.gov/35478046/Namki Hong, Sungjae Shin, Hyunjae Kim...
https://pubmed.ncbi.nlm.nih.gov/39485918/Manju Chandran
https://pubmed.ncbi.nlm.nih.gov/36382762/M R McClung, R B Wagman, P D Miller...
https://pubmed.ncbi.nlm.nih.gov/28144701/I Fogelman, G M Blake
https://pubmed.ncbi.nlm.nih.gov/11138687/National Taiwan University Hospital
Lead Sponsor